Invasive pneumococcal disease in Australia 2007 and 2008
DOI:
https://doi.org/10.33321/cdi.2012.36.10Keywords:
invasive pneumococcal diseaseAbstract
Errata published in CDI vol. 36 no. 4 (December 2012). The data in Figure 4 was a repeat of that in Figure 5, and the correct data for Figure 4 was not published The correct Figure is displayed in the attached Errata document.
Enhanced surveillance for invasive pneumococcal disease (IPD) was conducted in all Australian states and territories in 2007 and 2008 with comprehensive comparative data available since 2002. There were 1,477 cases of IPD notified to the National Notifiable Diseases Surveillance System in Australia in 2007; a notification rate of 7.0 cases per 100,000 population. In 2008 there were 1,628 cases; a notification rate of 7.6 cases per 100,000 population. The overall rate of IPD in Indigenous Australians was almost 6 times the rate in non-Indigenous Australians in 2007 and almost 5 times in 2008. By 2008, the 4th year of a funded universal infant 7-valent pneumococcal conjugate vaccine (7vPCV) program in Australia with a 3+0 schedule, vaccine serotype IPD notification rates in those identified as non-Indigenous decreased in all age groups compared with 2002 levels, most significantly by 96% in children aged less than 5 years. However, rates of disease in non-vaccine serotypes increased by 168% in children aged less than 5 years, including a four-fold increase in the number of cases due to serotype 19A. For the Aboriginal and Torres Strait Islander population, national pre-vaccination data are not available, as the vaccine program was funded for this group from 2001. From 2002 to 2008, the proportion of disease due to 7vPCV serotypes in children aged less than 5 years decreased by 77%, while disease due to non-7vPCV serotypes increased by 76%. In Indigenous adults (≥50 years), rates of 23vPPV serotypes increased by 92%. There were 120 deaths attributed to IPD in 2007 and 113 in 2008, although it should be noted that deaths may be under-reported. The number of invasive pneumococcal isolates with reduced penicillin susceptibility remains low and reduced susceptibility to third-generation cephalosporins is rare. Commun Dis Intell 2012;36(2):E151–E165.
Downloads
References
Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D, et al. Vaccine Preventable Diseases in Australia, 2005 to 2007. Commun Dis Intell 2010;34(Suppl):S1–S172.
Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook 9th edn. Canberra, Australia: National Health and Medical Research Council and the Department of Health and Ageing; 2008.
Roche P, Krause V, Andrews R, Carter L, Coleman D, Cook H, et al. Invasive pneumococcal disease in Australia, 2002. Commun Dis Intell 2003;27(2):466–477.
Roche P, Krause V, Bartlett B, Coleman D, Cook H, Davis C, et al. Invasive pneumococcal disease in Australia, 2004. Commun Dis Intell 2006;30(1):80–92.
Roche P, Krause V, Bartlett M, Coleman D, Cook H, Counahan M, et al. Invasive pneumococcal disease in Australia, 2003. Commun Dis Intell 2004;28(4):441–454.
Roche P, Krause V, Cook H. Invasive pneumococcal disease in Australia, 2005. Commun Dis Intell 2007;31(1):86–100.
Roche P, Krause V, Cook H, Bartlett M, Coleman D, Davis C, et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008;32(1):18–30.
National Health Security Act, No 174. 2007. Accessed on November 2009.
National Notifiable Diseases List 2008. Accessed on November 2009.
Top of page
Australian Bureau of Statistics. Population by age and sex, Australian States and Territories, Estimated Resident Population By Single Year of Age, Australia. Canberra: Australian Bureau of Statistics; 2008. Report No: 3201.0.
Communicable Diseases Network Australia. Australian national nofiable diseases case definitions – Pneumococcal disease (invasive) case definition. 2004. Accessed on 27 March 2010.
Miller E, Andrews N, Waight P, Slack M, George R. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11(10):760–768.
Pilishvili T, Lexau C, Farley M, Hadler J, Harrison L, Bennett N, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32–41.
McIntyre P, Chiu C, Jayasinghe S, Menzies R, Krause V, Cook H, et al. Reduction in 19A invasive pneumococcal diseases in Indigenous Australian children receiving conjugate pneumococcal vaccine with polysaccharide booster. In: Pneumococci and Pneumococcal Diseases Symposium. Tel Aviv; 2010.
Stubbs E, Hare K, Wilson C, Morris P, Leach A. Streptococcus pneumoniae and noncapsular Haemophilus influenzae nasal carriage and hand contamination in children: A comparison of two populations at risk of otitis media. Pediatr Infect Dis J 2005;24(5):423–428.
Singleton R, Hennessey T, Bulkow L, Hammitt L, Zulz T, Hurlburt D, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent penumococcal conjugate vaccine coverage. JAMA 2007;297(16):1784–1792.
Weatherholtz R, Millar E, Moulton L, Reid R, Rudolph K, Santosham M, et al. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis 2010;50(9):1238–1246.
Jardine A, Menzies R, McIntyre P. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 2010;29(7):607–612.
Jardine A, Menzies R, Deeks S, Patel M, McIntyre P. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J 2009;28(9):761–765.
Downloads
Additional Files
Published
How to Cite
License
Copyright (c) 2012 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
